Substratification of patients with newly diagnosed standard-risk multiple myeloma

Moritz Binder, S Vincent Rajkumar, Rhett P. Ketterling, Angela Dispenzieri, Martha Lacy, Morie Gertz, Francis K. Buadi, Suzanne R. Hayman, Yi L. Hwa, Steven R. Zeldenrust, John A. Lust, Stephen J Russell, Nelson Leung, Prashant Kapoor, Ronald S. Go, Wilson Gonsalves, Robert A. Kyle, Shaji K Kumar

Research output: Contribution to journalArticle

Abstract

Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Among them, advanced age, extremes of body mass index, non-hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard-risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high-risk patients. Two or more adverse factors were present in 17% of standard-risk patients and were associated with OS comparable to high-risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard-risk patients was improved using score groups compared to ISS stages. Patients with standard-risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high-risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.

Original languageEnglish (US)
JournalBritish journal of haematology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Multiple Myeloma
Survival
Confidence Intervals
Abnormal Karyotype
Lymphocyte Count
Cytogenetics
Body Mass Index

Keywords

  • multiple myeloma
  • prognosis
  • risk stratification

ASJC Scopus subject areas

  • Hematology

Cite this

Substratification of patients with newly diagnosed standard-risk multiple myeloma. / Binder, Moritz; Rajkumar, S Vincent; Ketterling, Rhett P.; Dispenzieri, Angela; Lacy, Martha; Gertz, Morie; Buadi, Francis K.; Hayman, Suzanne R.; Hwa, Yi L.; Zeldenrust, Steven R.; Lust, John A.; Russell, Stephen J; Leung, Nelson; Kapoor, Prashant; Go, Ronald S.; Gonsalves, Wilson; Kyle, Robert A.; Kumar, Shaji K.

In: British journal of haematology, 01.01.2019.

Research output: Contribution to journalArticle

Binder, Moritz ; Rajkumar, S Vincent ; Ketterling, Rhett P. ; Dispenzieri, Angela ; Lacy, Martha ; Gertz, Morie ; Buadi, Francis K. ; Hayman, Suzanne R. ; Hwa, Yi L. ; Zeldenrust, Steven R. ; Lust, John A. ; Russell, Stephen J ; Leung, Nelson ; Kapoor, Prashant ; Go, Ronald S. ; Gonsalves, Wilson ; Kyle, Robert A. ; Kumar, Shaji K. / Substratification of patients with newly diagnosed standard-risk multiple myeloma. In: British journal of haematology. 2019.
@article{0507a2f0ac694f7596a7baae90dc1862,
title = "Substratification of patients with newly diagnosed standard-risk multiple myeloma",
abstract = "Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Among them, advanced age, extremes of body mass index, non-hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard-risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95{\%} confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95{\%} CI 0·41–0·72, P < 0·001) experienced better OS than high-risk patients. Two or more adverse factors were present in 17{\%} of standard-risk patients and were associated with OS comparable to high-risk patients (HR 0·91, 95{\%} CI 0·67–1·24, P = 0·548). Predictive power among standard-risk patients was improved using score groups compared to ISS stages. Patients with standard-risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high-risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.",
keywords = "multiple myeloma, prognosis, risk stratification",
author = "Moritz Binder and Rajkumar, {S Vincent} and Ketterling, {Rhett P.} and Angela Dispenzieri and Martha Lacy and Morie Gertz and Buadi, {Francis K.} and Hayman, {Suzanne R.} and Hwa, {Yi L.} and Zeldenrust, {Steven R.} and Lust, {John A.} and Russell, {Stephen J} and Nelson Leung and Prashant Kapoor and Go, {Ronald S.} and Wilson Gonsalves and Kyle, {Robert A.} and Kumar, {Shaji K}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/bjh.15800",
language = "English (US)",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Substratification of patients with newly diagnosed standard-risk multiple myeloma

AU - Binder, Moritz

AU - Rajkumar, S Vincent

AU - Ketterling, Rhett P.

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Gertz, Morie

AU - Buadi, Francis K.

AU - Hayman, Suzanne R.

AU - Hwa, Yi L.

AU - Zeldenrust, Steven R.

AU - Lust, John A.

AU - Russell, Stephen J

AU - Leung, Nelson

AU - Kapoor, Prashant

AU - Go, Ronald S.

AU - Gonsalves, Wilson

AU - Kyle, Robert A.

AU - Kumar, Shaji K

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Among them, advanced age, extremes of body mass index, non-hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard-risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high-risk patients. Two or more adverse factors were present in 17% of standard-risk patients and were associated with OS comparable to high-risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard-risk patients was improved using score groups compared to ISS stages. Patients with standard-risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high-risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.

AB - Despite the absence of high-risk cytogenetics and lower International Staging System (ISS) stages, a subset of patients with multiple myeloma (MM) experience poor overall survival (OS). We studied 1461 patients with newly diagnosed MM to identify patient and disease characteristics that predict a high-risk phenotype among standard-risk patients. Fifty-six percent of all patients presented with standard-risk disease. Among them, advanced age, extremes of body mass index, non-hyperdiploid karyotype and abnormal lymphocyte counts were associated with worse OS. Standard-risk patients with 0–1 of these adverse factors (hazard ratio [HR] 0·32, 95% confidence interval [CI] 0·24–0·43, P < 0·001) and 2 adverse factors (HR 0·54, 95% CI 0·41–0·72, P < 0·001) experienced better OS than high-risk patients. Two or more adverse factors were present in 17% of standard-risk patients and were associated with OS comparable to high-risk patients (HR 0·91, 95% CI 0·67–1·24, P = 0·548). Predictive power among standard-risk patients was improved using score groups compared to ISS stages. Patients with standard-risk MM are a heterogeneous group with one in six patients experiencing OS comparable to high-risk disease. Patients at risk can be identified using readily available patient and disease characteristics. These findings emphasize the importance of accurate risk stratification and help explain part of the heterogeneity observed in clinical practice.

KW - multiple myeloma

KW - prognosis

KW - risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85061581102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061581102&partnerID=8YFLogxK

U2 - 10.1111/bjh.15800

DO - 10.1111/bjh.15800

M3 - Article

C2 - 30768679

AN - SCOPUS:85061581102

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -